Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salar L.)

Table 3 Gene sets significantly up-regulated 7 days after the end of the medication period (day 14).

Rank	Gene Sets – Up-regulated	Size	Nom P-value	FDR (%)
1	Prostanoid biosynthetic process	19	0.0	0.38
2	Prostaglandin biosynthetic process	19	0.0	0.19
3	Cytokine binding	21	0.0	0.37
4	Regulation of macrophage activation	15	0.0	0.44
5	Ecosanoid biosynthetic process	29	0.0	0.49
6	Ecosanoid metabolic process	29	0.0	0.41
7	Carbohydrate binding	34	0.0	0.47
8	Macrophage activation	18	0.0	0.6
9	Myeloid leukocyte activation	18	0.0	0.54
10	Sugar binding	29	0.0	0.98
11	Monosaccharide binding	16	0.0	1.79
12	Glutamate dehydrogenase [NAD(P)+] activity	14	0.0	2.99
13	Leukocyte activation	37	0.0	3.58
14	Activation of MAPK activity	12	0.0	4.6
15	Intracellular protein transport	41	0.0	5.8
16	Protein amino acid N-linked glycosylation via asparagines	17	0.0	5.94
17	Peptidyl-asparagine modification	17	0.0	5.59
18	Oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor	17	0.0	5.54
19	Mannose binding	12	0.01	5.34
20	Antigen processing and presentation of exogenous peptide antigen via MHC class II	24	0.0	8.97
21	Antigen processing and presentation of peptide antigen via MHC class II	24	0.0	8.55
22	Transition metal ion binding	31	0.0	8.69
23	Peptidyl-amino acid modification	24	0.01	10.94

Gene set enrichment analysis (GSEA) with a false discovery rate (FDR) cut-off of approximately 10%. Nominal P values are also shown, as well as gene set sizes (number of genes in each gene set). No gene sets were significantly down-regulated 7 days after the end of the medication period, with a FDR lower than about 10%.